|Bid||239.56 x 800|
|Ask||245.01 x 900|
|Day's range||239.56 - 244.04|
|52-week range||129.21 - 275.87|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||36.65|
|Forward dividend & yield||3.40 (1.39%)|
|Ex-dividend date||12 Nov 2021|
|1y target est||N/A|
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.
Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.